Skip to content

Lifestyle Modification and Metformin Use in the Treatment of HIV

Strategies for the Treatment of HIV Associated Metabolic Syndrome

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00399360
Enrollment
50
Registered
2006-11-14
Start date
2006-12-31
Completion date
2012-06-30
Last updated
2012-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections, Metabolic Syndrome X

Keywords

HIV, Metabolic Syndrome, Lifestyle Modification, Metformin, Treatment Experienced

Brief summary

A healthy diet and exercise have improved the health of people without human immunodeficiency virus (HIV) who have Metabolic Syndrome. In this study we would like to find out if the same benefit can be seen in people with HIV and Metabolic Syndrome. Patients with Metabolic Syndrome usually have a large waist, high blood cholesterol levels, high blood pressure, and high blood sugar levels. These are risk factors, which may increase one's chance of developing heart disease and/or diabetes. The purpose of the study is to evaluate the effects of different methods of treating HIV associated Metabolic Syndrome. The groups are: 1) a lifestyle modification program plus metformin (also known as glucophage), 2) lifestyle modification plus placebo, 3) metformin alone or 4) placebo alone. The lifestyle modification program consists of nutrition and exercise sessions with the goal of improving body composition, heart health, and ways to lower the risk of developing diabetes.

Detailed description

After two initial screening visits with medical and nutrition staff for informed consent and determination of eligibility qualifying subjects will be seen for a baseline visit. At baseline subjects will have an interval history and physical exam, lipodystrophy evaluation by investigator and patient report. Bloods will be taken for insulin, glucose, HgbA1c, lipid studies, creatinine, liver function, serum lactate, urine pregnancy (women), CD4, viral load, and complete blood count (CBC). Metabolic assessment will include a 2-hour oral glucose tolerance test and indirect calorimetry. Carotid ultrasound will be done for assessment of intima-media thickness. Body composition will be assessed by dual energy x-ray absorptiometry (DEXA), single-slice magnetic resonance imaging (MRI) scanning through the abdomen and mid thigh, magnetic resonance spectroscopy scanning to assess intramyocellular lipid of the calf, anthropometric measurements, and Cardiac computed tomography (CT) will be done. After the baseline visit, subjects will be randomized to 1 of 4 groups: 1) a lifestyle modification program plus metformin (also known as glucophage), 2) lifestyle modification plus placebo, 3) metformin alone or 4) placebo alone. The starting dose of metformin will be 500mg twice daily and this will increase to 850mg twice daily at the 3-month visit. An identical visit to that at baseline will be repeated at 12-months. Subjects will return at 1 month for an interval history and physical exam, assessment of compliance and side effects. Blood will be collected for CBC, lactate, liver function, and creatinine. Women will have a urine pregnancy. A 6-month visit will include an interval history and physical exam, assessment of compliance and side effects, 2 hour oral glucose tolerance test, fasting bloods (glucose, lipid panel, creatinine, liver function, serum lactate, CBC) will be done, a urine pregnancy will be checked in women. Carotid ultrasound will be done and body composition will be assessed by anthropometric measurements and DEXA scan. There will also be a short visit at 3 and 9 months to obtain an interval history and physical exam, safety labs (serum lactate, CBC, liver function, and creatinine), urine pregnancy (women). Subjects randomized to metformin or placebo will increase their dose from 500mg twice daily to 850mg twice daily at the 3 month visit. At each of the visits review of a 4 day food record will occur. Those randomized to lifestyle modification will attend weekly sessions with a study investigator to cover a core-curriculum that is modeled after the Diabetes Prevention Program (DPP) intervention. The primary goals of the lifestyle modification program are derived from a combination of recommendations from the American Academy of Clinical Endocrinologists (AACE) and National Cholesterol Education Program (NCEP). The goals are to eat less than or equal to 35% of total calories from fat (less than 7% from saturated fat, up to 10% from polyunsaturated fat with emphasis on sources of omega 3 fatty acids and reduction of trans fatty acids, up to 20% from monounsaturated fats), and 25-35g of fiber per day. The intensity of the counseling sessions will decrease in months 10 through 12 to biweekly counseling session with study investigators and biweekly phone contact, alternating. In addition to the program outlined above, those randomized to the lifestyle modification group will also participate in progressive resistance training. Each training session will begin with a 5 minute warm-up on a stationary bicycle at 50% of the estimated maximal heart rate (maximal heart rate=220-age). All sessions will be monitored by a licensed physical therapist. Immediately after the warm-up, a standard flexibility routine will be performed to minimize the risk of injury. Then, the aerobic training protocol will be performed. The aerobic training program will follow the general guidelines established by the American College of Sports Medicine. Training will be performed using a standard stationary bicycle. Aerobic/endurance exercise will be performed with large muscle groups. Each subject will complete three supervised training sessions per week for 12 months. Strength training will be performed using Keiser equipment. Selected muscle groups will be trained alternating upper and lower exercises in the following order: 1) hip extension, 2) lateral pull down, 3) knee extension, 4) elbow flexion, 5) knee flexion, and 6) chest press. Each repetition will include concentric and eccentric phases. Each muscle group will be trained individually 3 times per week, on alternate days. The subjects will perform three sets of 10 repetitions each for every muscle group, resting 2-3 seconds between repetitions, 2 minutes between sets, and 4 minutes between muscle groups. The 1 repetition maximum will be measured every 3-4 weeks for the first 6 months and it will be repeated again at the 9 and 12 month visits. The relative intensity will increase from 60-80% of the 1 repetition maximum over 6 months. Subjects not randomized to training will have a determination of 1 repetition maximum made at baseline, 6 and 12 months.

Interventions

DRUGMetformin

Starting at 500 mg twice daily and increasing to 850 mg twice daily after 3 Months

DRUGPlacebo

500 mg twice daily increasing to 850 mg twice daily after 3 Months

BEHAVIORALLifestyle Modification

Lifestyle Modification

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 and ≤ 65 years of age * HIV positive, on a stable combination antiretroviral regimen for \> 6 months, including but not limited to either 2 nucleoside reverse transcriptase inhibitors (NRTI) and a non-nucleoside reverse transcriptase inhibitors (NNRTI) or protease inhibitor (PI), or a triple NRTI regimen * Ability and motivation to modify behavior and make lifestyle changes * NCEP-Adult Treatment Panel III defined metabolic syndrome, as defined by 3 out of 5 of the following: 1) Waist circumference greater than 102 cm (40 in) in men and 88 cm (35 in) in women, 2) Triglycerides ≥ 150 mg/dL or current anti-lipolytic drug treatment, 3) high-density lipoprotein less than 40mg/dL in men and 50 mg/dL in women, 4) Blood pressure ≥ 130/85 mmHg or current antihypertensive drug treatment, 5) Fasting glucose ≥ 100 mg/dL

Exclusion criteria

* Any new serious opportunistic infection within the past 6 weeks * History of unstable angina, aortic stenosis, uncontrolled hypertension, severe neuropathy, arthritis or other contraindication to exercise * Current therapy with insulin or other diabetic agent, fasting blood sugar \> 126 * Requiring parenteral nutrition or parenteral glucocorticoid therapy or oral glucocorticoid therapy * Estrogen, progestational derivative, or ketoconazole use within 3 months * New antiretroviral regimen in the past 6 months * Serum creatinine \> 1.5 mg/dL (males) and 1.4 mg/dL (females), serum glutamic pyruvic transaminase-liver function (SGPT), \> 2.5 upper limit of normal (ULN), Lactate \> 2.0 ULN, hemoglobin \< 10.0 mg/dL * Current substance and/or alcohol abuse * Known hypersensitivity to Metformin * Congestive heart failure requiring pharmacologic treatment * Use of cimetidine or planned use during the study period * Hypertrophic obstructive cardiomyopathy * Pregnant or actively seeking pregnancy, breastfeeding * Testosterone use for non-physiologic purposes, or physiologic testosterone replacement for \< 3 months. * Presence of active AIDS including cancers * Current viral, bacterial or other infections (excluding HIV) * Weight loss in the past 3 months of greater than 10 pounds * Nitrates or other medications that can alter endothelial function * Contraindication to beta blocker or nitroglycerin use * Patients with previous allergic reactions to iodine-containing contrast media or to iodine

Design outcomes

Primary

MeasureTime frameDescription
Coronary Artery Calcium Scorebaseline and 12 monthsComputed tomography (CT) imaging was performed using a SOMATOM Sensation (Siemens Medical Solutions, Forcheim, Germany) 64-slice CT scanner. Agatston calcium score was calculated using CT images. The total Agatston score is calculated by summing up the scores of the individual calcifications in all slices of the CT scan. An absolute Agatston score of less than 10 indicates minimal overall atherosclerosis (plaques) in the coronary arteries. The change in the coronary artery calcium score between baseline and 12 months is reported.
Waist Circumferencebaseline and 12 monthsIliac waist circumference measurements were obtained using an inelastic tape measure. All measurements were obtained in triplicate, with the patient undressed, and then averaged. The change of the waist circumference measurement between baseline and 12 months is reported.
High Density Lipoprotein (HDL)baseline and 12 monthsHigh density lipoprotein (HDL) was determined after an overnight fast. The change in HDL between baseline and 12 months is reported.
Glucosebaseline and 12 monthsGlucose level was determined after an overnight fast. The change in glucose between baseline and 12 months is reported.
Systolic Blood Pressurebaseline and 12 monthsSystolic blood pressure was measured after 5 minutes rest. The in systolic blood pressure between baseline and 12 months is reported.
Carotid Intima Media Thicknessbaseline and 12 monthsCarotid intima media thickness imaging of the common carotid artery was conducted using a high-resolution 7.5-MHz phased-array transducer (SONOS 2000/2500. The change of the carotid intima media thickness measurement between baseline and 12 months is reported.

Secondary

MeasureTime frameDescription
Abdominal Visceral Adipositybaseline and 12 monthsAbdominal visceral adipose area was assess by magnetic resonance imaging at the lvel of the L4 pedicle. The change in abdominal visceral adiposity between baseline and 12 months is reported.
Cardiorespiratory Fitnessbaseline and 12 monthsA submaximal exercise stress test was conducted on a cycle ergometer to measure endurance. Subjects cycled between 50-60 revolutions per minute and the workload was progressively increased in increments of 50 watts in stages lasting 3 minutes. Once subjects became fatigued or reached their submaximal heart rate (220-age x 85), the test was stopped and separate readings of heart rate and blood pressure were measured at 1, 3, and 5 min of recovery. Weight-adjusted maximum oxygen consumption (VO2max; ml/kg per minute) was determined. The change in cardiorespiratory fitness between baseline and 12 months is reported.
Intramyocellular Lipidbaseline and 12 monthsIntramyocellular lipid (IMCL) of the tibialis anterior was determined using 1H-magnetic resonance spectroscopy (Siemens, Munich, Germany). The change in the intramyocellular lipid measurement between baseline and 12 months is reported.
C-reactive Proteinbaseline and 12 monthsHigh sensitivity C-reactive protein was determined by R&D Systems (Minneapolis, MN) kit. The change in C-reactive protein between baseline and 12 months is reported.

Countries

United States

Participant flow

Participants by arm

ArmCount
No Lifestyle Modification and Placebo
Participants did not participate in lifestyle modification and took a placebo capsule 500mg twice daily x 3 months, which was increased to 850mg twice daily at the 3 month visit for the duration of the study.
11
Lifestyle Modification and Placebo
Participants participated in lifestyle modification sessions 3 times a week for the duration of the study and took a placebo capsule 500mg twice daily for 3 months which was increased to 850mg twice daily at the 3 month visit for the duration of the study.
11
No Lifestyle Modification and Metformin
Participants did not participate in lifestyle modification and took metformin 500mg twice daily for 3 months, this was increased to 850mg twice daily at the 3 month visit for the duration of the study.
13
Lifestyle Modification and Metformin
Participants participated in lifestyle modification sessions 3 times a week for the duration of the study and took metformin 500mg twice daily for 3 months which was increased to 850mg twice daily at the 3 month visit for the duration of the study.
15
Total50

Withdrawals & dropouts

PeriodReasonFG000FG001FG002FG003
Overall StudyAdverse Event0010
Overall StudyLost to Follow-up2124
Overall StudyWithdrawal by Subject0202

Baseline characteristics

CharacteristicLifestyle Modification and PlaceboNo Lifestyle Modification and MetforminLifestyle Modification and MetforminNo Lifestyle Modification and PlaceboTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
11 Participants13 Participants15 Participants11 Participants50 Participants
Age Continuous49 years
STANDARD_DEVIATION 8
45 years
STANDARD_DEVIATION 9
47 years
STANDARD_DEVIATION 8
47 years
STANDARD_DEVIATION 6
47 years
STANDARD_DEVIATION 7
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants1 Participants0 Participants0 Participants1 Participants
Race (NIH/OMB)
Black or African American
4 Participants3 Participants5 Participants4 Participants16 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants0 Participants0 Participants0 Participants1 Participants
Race (NIH/OMB)
White
6 Participants9 Participants10 Participants7 Participants32 Participants
Region of Enrollment
United States
11 participants13 participants15 participants11 participants50 participants
Sex: Female, Male
Female
3 Participants3 Participants2 Participants4 Participants12 Participants
Sex: Female, Male
Male
8 Participants10 Participants13 Participants7 Participants38 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —— / —
other
Total, other adverse events
0 / 112 / 113 / 135 / 15
serious
Total, serious adverse events
0 / 110 / 110 / 130 / 15

Outcome results

Primary

Carotid Intima Media Thickness

Carotid intima media thickness imaging of the common carotid artery was conducted using a high-resolution 7.5-MHz phased-array transducer (SONOS 2000/2500. The change of the carotid intima media thickness measurement between baseline and 12 months is reported.

Time frame: baseline and 12 months

Population: All data were included in the analysis by intention to treat principle. For participants who did not complete a 12-month visit, last observation carried forward was performed for those participants for whom interim data post the baseline visit was available.

ArmMeasureValue (MEAN)Dispersion
No Lifestyle Modification and PlaceboCarotid Intima Media Thickness-0.02 mmStandard Error 0.03
Lifestyle Modification and PlaceboCarotid Intima Media Thickness-0.02 mmStandard Error 0.04
No Lifestyle Modification and MetforminCarotid Intima Media Thickness0.00 mmStandard Error 0.01
Lifestyle Modification and MetforminCarotid Intima Media Thickness0.03 mmStandard Error 0.02
p-value: 0.37ANOVA
Primary

Coronary Artery Calcium Score

Computed tomography (CT) imaging was performed using a SOMATOM Sensation (Siemens Medical Solutions, Forcheim, Germany) 64-slice CT scanner. Agatston calcium score was calculated using CT images. The total Agatston score is calculated by summing up the scores of the individual calcifications in all slices of the CT scan. An absolute Agatston score of less than 10 indicates minimal overall atherosclerosis (plaques) in the coronary arteries. The change in the coronary artery calcium score between baseline and 12 months is reported.

Time frame: baseline and 12 months

Population: All data were included in the analysis by intention to treat principle. For participants who did not complete a 12-month visit, last observation carried forward was performed for those participants for whom interim data post the baseline visit was available.

ArmMeasureValue (MEAN)Dispersion
No Lifestyle Modification and PlaceboCoronary Artery Calcium Score43 Agatston scoreStandard Error 30
Lifestyle Modification and PlaceboCoronary Artery Calcium Score19 Agatston scoreStandard Error 7
No Lifestyle Modification and MetforminCoronary Artery Calcium Score1 Agatston scoreStandard Error 1
Lifestyle Modification and MetforminCoronary Artery Calcium Score-4 Agatston scoreStandard Error 6
p-value: 0.03ANOVA
Primary

Glucose

Glucose level was determined after an overnight fast. The change in glucose between baseline and 12 months is reported.

Time frame: baseline and 12 months

ArmMeasureValue (MEAN)Dispersion
No Lifestyle Modification and PlaceboGlucose-7 mg/dLStandard Error 5
Lifestyle Modification and PlaceboGlucose3 mg/dLStandard Error 3
No Lifestyle Modification and MetforminGlucose2 mg/dLStandard Error 2
Lifestyle Modification and MetforminGlucose-7 mg/dLStandard Error 3
p-value: 0.13ANOVA
Primary

High Density Lipoprotein (HDL)

High density lipoprotein (HDL) was determined after an overnight fast. The change in HDL between baseline and 12 months is reported.

Time frame: baseline and 12 months

Population: All data were included in the analysis by intention to treat principle. For participants who did not complete a 12-month visit, last observation carried forward was performed for those participants for whom interim data post the baseline visit was available.

ArmMeasureValue (MEAN)Dispersion
No Lifestyle Modification and PlaceboHigh Density Lipoprotein (HDL)-2 mg/dLStandard Error 1
Lifestyle Modification and PlaceboHigh Density Lipoprotein (HDL)2 mg/dLStandard Error 1
No Lifestyle Modification and MetforminHigh Density Lipoprotein (HDL)0 mg/dLStandard Error 2
Lifestyle Modification and MetforminHigh Density Lipoprotein (HDL)4 mg/dLStandard Error 1
p-value: 0.08ANOVA
Primary

Systolic Blood Pressure

Systolic blood pressure was measured after 5 minutes rest. The in systolic blood pressure between baseline and 12 months is reported.

Time frame: baseline and 12 months

ArmMeasureValue (MEAN)Dispersion
No Lifestyle Modification and PlaceboSystolic Blood Pressure-5 mm HgStandard Error 4
Lifestyle Modification and PlaceboSystolic Blood Pressure-2 mm HgStandard Error 6
No Lifestyle Modification and MetforminSystolic Blood Pressure-2 mm HgStandard Error 4
Lifestyle Modification and MetforminSystolic Blood Pressure-6 mm HgStandard Error 4
p-value: 0.85ANOVA
Primary

Waist Circumference

Iliac waist circumference measurements were obtained using an inelastic tape measure. All measurements were obtained in triplicate, with the patient undressed, and then averaged. The change of the waist circumference measurement between baseline and 12 months is reported.

Time frame: baseline and 12 months

Population: All data were included in the analysis by intention to treat principle. For participants who did not complete a 12-month visit, last observation carried forward was performed for those participants for whom interim data post the baseline visit was available.

ArmMeasureValue (MEAN)Dispersion
No Lifestyle Modification and PlaceboWaist Circumference-1.9 cmStandard Error 1.4
Lifestyle Modification and PlaceboWaist Circumference-0.1 cmStandard Error 1.7
No Lifestyle Modification and MetforminWaist Circumference0.3 cmStandard Error 2
Lifestyle Modification and MetforminWaist Circumference-1.4 cmStandard Error 1.8
p-value: 0.8ANOVA
Secondary

Abdominal Visceral Adiposity

Abdominal visceral adipose area was assess by magnetic resonance imaging at the lvel of the L4 pedicle. The change in abdominal visceral adiposity between baseline and 12 months is reported.

Time frame: baseline and 12 months

ArmMeasureValue (MEAN)Dispersion
No Lifestyle Modification and PlaceboAbdominal Visceral Adiposity-22.6 cm2Standard Error 14.5
Lifestyle Modification and PlaceboAbdominal Visceral Adiposity-1.5 cm2Standard Error 14
No Lifestyle Modification and MetforminAbdominal Visceral Adiposity-28.2 cm2Standard Error 15.3
Lifestyle Modification and MetforminAbdominal Visceral Adiposity-35.0 cm2Standard Error 27.7
p-value: 0.63ANOVA
Secondary

Cardiorespiratory Fitness

A submaximal exercise stress test was conducted on a cycle ergometer to measure endurance. Subjects cycled between 50-60 revolutions per minute and the workload was progressively increased in increments of 50 watts in stages lasting 3 minutes. Once subjects became fatigued or reached their submaximal heart rate (220-age x 85), the test was stopped and separate readings of heart rate and blood pressure were measured at 1, 3, and 5 min of recovery. Weight-adjusted maximum oxygen consumption (VO2max; ml/kg per minute) was determined. The change in cardiorespiratory fitness between baseline and 12 months is reported.

Time frame: baseline and 12 months

Population: All data were included in the analysis by intention to treat principle. For participants who did not complete a 12-month visit, last observation carried forward was performed for those participants for whom interim data post the baseline visit was available.

ArmMeasureValue (MEAN)Dispersion
No Lifestyle Modification and PlaceboCardiorespiratory Fitness-0.7 ml/kg/minStandard Error 1.6
Lifestyle Modification and PlaceboCardiorespiratory Fitness2.0 ml/kg/minStandard Error 1.2
No Lifestyle Modification and MetforminCardiorespiratory Fitness-1.3 ml/kg/minStandard Error 0.9
Lifestyle Modification and MetforminCardiorespiratory Fitness3.7 ml/kg/minStandard Error 1.8
p-value: 0.05ANOVA
Secondary

C-reactive Protein

High sensitivity C-reactive protein was determined by R&D Systems (Minneapolis, MN) kit. The change in C-reactive protein between baseline and 12 months is reported.

Time frame: baseline and 12 months

ArmMeasureValue (MEAN)Dispersion
No Lifestyle Modification and PlaceboC-reactive Protein-0.27 mg/lStandard Error 0.66
Lifestyle Modification and PlaceboC-reactive Protein-1.19 mg/lStandard Error 1.11
No Lifestyle Modification and MetforminC-reactive Protein0.47 mg/lStandard Error 0.6
Lifestyle Modification and MetforminC-reactive Protein-1.92 mg/lStandard Error 0.93
p-value: 0.1ANOVA
Secondary

Intramyocellular Lipid

Intramyocellular lipid (IMCL) of the tibialis anterior was determined using 1H-magnetic resonance spectroscopy (Siemens, Munich, Germany). The change in the intramyocellular lipid measurement between baseline and 12 months is reported.

Time frame: baseline and 12 months

ArmMeasureValue (MEAN)Dispersion
No Lifestyle Modification and PlaceboIntramyocellular Lipid0.6 mmol/kgStandard Error 0.2
Lifestyle Modification and PlaceboIntramyocellular Lipid-0.4 mmol/kgStandard Error 0.2
No Lifestyle Modification and MetforminIntramyocellular Lipid0.8 mmol/kgStandard Error 0.4
Lifestyle Modification and MetforminIntramyocellular Lipid0.1 mmol/kgStandard Error 0.2
p-value: 0.02ANOVA

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026